7.11
-0.1(-1.39%)
Currency In USD
Address
910 Clopper Road
Gaithersburg, MD 20878
United States of America
Phone
240 654 1450
Website
Sector
Healthcare
Industry
Biotechnology
Employees
59
First IPO Date
May 26, 2017
| Name | Title | Pay | Year Born |
| Dr. Vipin K. Garg Ph.D. | President, Chief Executive Officer & Director | 986,142 | 1958 |
| Mr. Raymond M. Jordt M.B.A. | Chief Business Officer | 578,850 | 1973 |
| Dr. M. Scot Roberts Ph.D. | Chief Scientific Officer | 599,255 | 1959 |
| Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS | Chief Medical Officer | 681,809 | 1953 |
| Mr. Gregory L. Weaver CPA, M.B.A. | Chief Financial Officer | 0 | 1956 |
| Mr. Andrew Shutterly M.S. | Principal Financial & Accounting Officer and Corporate Controller | 0 | 1988 |
| Mr. Bertrand Georges Ph.D. | Chief Technology Officer | 0 | N/A |
| Mr. Tony Blandin B.S. | Vice President of Quality & Compliance Management | 0 | N/A |
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.